News
Global collaboration aims to advance breast cancer treatments

A research group bringing together 1,400 cancer centres and 21,000 oncology researchers is collaborating with a life sciences firm to target new breast cancer treatments.
ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences have announced a multi-year research collaboration.
Caris is pairing its genomic expertise and AI and machine learning algorithms with ECOG-ACRIN’s vast research capability.
The first project is underway and leverages the tumour tissue samples from the TAILORx (trial assigning individualised options for treatment – Rx), breast cancer clinical trial.
TAILORx is one of the world’s largest breast cancer research resources.
It will explore early-stage breast cancer, where the risk of recurrence is a primary concern for many people.
Approximately 60 per cent of newly-diagnosed breast cancer cases are in the early stage, with no spread to surrounding lymph nodes.
While there has been an overall 42 per cent decline in breast cancer deaths over the last 30 years—due to increased use of mammograms, earlier diagnoses, and more effective treatments—there is a persistent mortality gap between minority patients and white patients.
A TAILORx analysis published in JAMA Surgery is the first to show that racial and ethnic differences in locoregional breast cancer recurrence patterns are prevalent even in a clinical trial population with similar access to care.
As part of its new collaboration, Caris will perform comprehensive molecular characterisation on tumour tissues contributed by nearly 10,000 patients with early-stage breast cancer who participated in the TAILORx trial.
Participants have been followed for 11 years or more, with planned follow-up for 20 years.
Caris will couple its molecular testing with its advanced AI and machine learning algorithms. Data from the project will also be made publicly available after a designated time-period following completion of the research project plan in an appropriate NCI database.
Peter O’Dwyer, group co-chair of ECOG-ACRIN, said: “Our collaboration with Caris has deep roots, aligned interests, and a commitment to develop the best science in the service of early detection and treatment of cancer. The promise of the joint effort is to provide broad availability of cutting-edge options for cancer patients in their communities.”
George Sledge, chief medical officer of Caris, said:“I’m excited to build on the trial’s initial findings which prevented millions of women with early breast cancer from having to endure toxic treatments, to continue discerning valuable insights related to long term recurrence risk and to identify even more women who may benefit from more efficient treatment options.
“It is truly a full circle moment for me, as I’ve been involved with this landmark biomarker trial–the largest ever sponsored by the NCI–during trial development, patient enrollment, findings reporting and now the next phase of research of TAILORx with Caris.”
Mitchell Schnall, group co-chair of ECOG-ARIN, says: “Given the innovative capabilities offered by Caris, analysis of TAILORx biospecimens with cutting-edge AI approaches provides a great opportunity to discover superior biomarkers for risk stratification, prediction of recurrence and better understanding of racial disparities. The size and impact of TAILORx makes it a perfect study to lead off this collaboration.”
ECOG-ACRIN is a membership organisation that designs and conducts cancer research involving adults who have or are at risk of developing cancer.
It comprises nearly 1400 member institutions and 21,000 research professionals globally.
It is funded primarily by the US-based National Cancer Institute, part of the National Institutes of Health.
Diagnosis
AI maps how reproductive organs age differently during menopause
Cancer
Ovarian cancer cases rising among younger adults, study finds

Ovarian cancer cases are rising among younger adults in England, with bowel cancer showing a similar pattern, a new study suggests.
Researchers said excess weight is a key contributor, but is unlikely on its own to explain the pattern.
The authors wrote: “These patterns suggest that while similar risk factors across ages are likely, some cancers may have age-specific exposures, susceptibilities, or differences in screening and detection practices.”
They added: “Although overweight and obesity are linked to 10 of the 11 cancers evaluated and account for a substantial proportion of cancer cases, both BMI-attributable and BMI-non-attributable incidence rates have increased, though the latter more slowly, suggesting other contributors.”
The study analysed cancer incidence, meaning new diagnoses, in England between 2001 and 2019 across more than 20 cancer types, comparing adults aged 20 to 49 with those aged 50 and over.
Among younger women, cases of 16 out of 22 cancers increased significantly over the period, while among younger men, 11 out of 21 cancers increased significantly.
In particular, there was a significant rise in 11 cancers with known behavioural risk factors among adults under 50. These were thyroid, multiple myeloma, liver, kidney, gallbladder, bowel, pancreatic, endometrial, mouth, breast and ovarian cancers.
Rates of all 11 also rose significantly among adults aged 50 and over, with the notable exceptions of bowel and ovarian cancer.
Five cancers, endometrial, kidney, pancreatic, multiple myeloma and thyroid cancer, increased significantly faster in younger than in older women, while multiple myeloma increased faster in younger than in older men.
The researchers looked at established risk factors including smoking, alcohol intake, diet, physical inactivity and body mass index, a measure used to assess whether someone is underweight, a healthy weight, overweight or obese.
With the exception of mouth cancer, all 11 cancers were associated with obesity. Six, liver, bowel, mouth, pancreatic, kidney and ovarian, were also linked to smoking.
Four, liver, bowel, mouth and breast, were associated with alcohol intake. Three, bowel, breast and endometrial, were linked to physical inactivity, and one, bowel, was associated with dietary factors.
But apart from excess weight, trends in those risk factors over the past one to two decades were stable or improving among younger adults.
That suggests other factors may also play a part, including reproductive history, early-life or prenatal exposures, and changes in diagnosis and detection.
The study noted that red meat consumption fell among younger adults, while fibre intake remained stable or slightly improved in both sexes between 2009 and 2019, although more than 90 per cent of younger adults were still not eating enough fibre in 2018.
Established behavioural risk factors accounted for a substantial share of cancer cases.
Excess weight was the risk factor associated with most cancers in 2019, ranging from 5 per cent for ovarian cancer to 37 per cent for endometrial cancer.
The researchers said the findings were based on observational data, meaning the study could identify patterns but could not prove cause and effect.
They also noted there were no consistent long-term national data for several risk factors, that the analysis was limited to England rather than the UK, and that cancer remains far more common overall in older adults despite the rise in cases among younger people.
Pregnancy
Early miscarriage care could prevent 10,000 pregnancy losses a year, study finds
Entrepreneur7 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Ageing1 week agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says
News4 weeks agoCopper coil vs Mirena: Which is right for you?















